Effect of metformin on the magnitude of oxidative stress in patients with type 2 diabetes mellitus
https://doi.org/10.14341/probl20075313-7
Abstract
The final glycated products forming in diabetes contribute to the higher atherogenic oxidative modification of low-density lipoproteins (LDL). The impact of glycemic control on the parameters of free radical oxidation was comparatively studied in patients with type 2 diabetes who received metformin (Glucophage, Nycomed) (Group 1, n = 40) and sulfanylurea preparations (Group 2, n — 30, out of them 15 patients took maninil and 15 had diabeton) good glycemic control caused the magnitude of oxidative stress to reduce, which appeared as the decreased levels of primary (lipid hydroperoxides) and secondary (malonic dialdehyde) products of free radical oxidation in LDL and as the enhanced activity of antioxidative defense enzymes. However, with the identical degree of glycemic control, which was determined by the level concentrations of HbA1c and lipids in both groups, the plasma levels of lipid peroxides decreased by more than 5 times in Group 1 patients receiving metformin than in Group 2 patients and the rate of LDL oxidability reduced by 4.5 times. Such a marked effect of metformin on the attenuated manifestations of oxidative stress is indicative of its antioxidative effect independent of the hypoglycemic effect of the drug.
About the Authors
L. V. NedosugovaI.M.Sechenov Moscow Medical Academy
Russian Federation
V. Z. Lankin
Research Institute of Cardiology named after A. L. Myasnikov of the Russian Cardiology Research and Production Complex of the Ministry of Health and Social Development of the Russian Federation
Russian Federation
S. M. Reznik
I.M.Sechenov Moscow Medical Academy
Russian Federation
M. I. Balabolkin
I.M.Sechenov Moscow Medical Academy
Russian Federation
K. V. Antonova
I.M.Sechenov Moscow Medical Academy
Russian Federation
N. E. Arzamastseva
Research Institute of Cardiology named after A. L. Myasnikov of the Russian Cardiology Research and Production Complex of the Ministry of Health and Social Development of the Russian Federation
Russian Federation
G. G. Konovalova
Research Institute of Cardiology named after A. L. Myasnikov of the Russian Cardiology Research and Production Complex of the Ministry of Health and Social Development of the Russian Federation
Russian Federation
References
1. Доборджгинидзе Л. М., Грацианский Н. А.//Сахарный диабет. -2001. -№ 2. -С. 41-47.
2. Коновалова Г. Г., Ланкин В. 3., Тихазе А. К. и др.//Бюл. экспер. биол. -2003. -Т. 136, № 8. -С. 163-166.
3. Ланкин В. 3., Тихазе А. К., Беленков Ю. Н.//Кардиология. -2000. -Т. 40, № 7. -С. 48-61.
4. Ланкин В. 3., Тихазе А. К., Беленков Ю. Н. Свободнорадикальные процессы в норме и при патологических состояниях: Пособие для врачей. -М., 2001.
5. Ланкин В. 3., Тихазе А. К., Беленков Ю. И.//Кардиология. -2004. -Т. 44, № 2. -С. 72-81.
6. Ланкин В. 3., Лисина М. О., Арзамасцева Н. Е. и др.//Бюл. экспер. биол. -2005. -Т. 140, № 1. -С. 41-43.
7. Battah S., Ahmed N., Thornalley P.//International Congress Series: Proceedings of the 7-th International Maillard Symposium. -Amsterdam; New York, 2002.
8. Baynes J. W., Thorpe S. R.//Free Rad. Biol. Med. -2000. -Vol. 28. -P. 1708-1716.
9. Beisswenger P., Howell S, Touchette A. et al.//Diabetes. -1999. -Vol. 48. -P. 198-202.
10. Beisswenger P., Howell S., Smith K., Szeergold B.//Biochim. Biophys. Acta. -2003. -Vol. 1637. -P. 98-106.
11. Brownlee M.//Nature. -2001. -Vol. 414. -P. 813-820.
12. Cheng C., Chang H.//Drug Metab. Rev. -2000. -Vol. 32. -Suppl. 2. -P. 266.
13. Fore W. W.//Med. Clin. N. Am. -1995. -Vol. 79, N 2. -P. 287-298.
14. Garber A. J.//Med. Clin. N. Am. -1998. -Vol. 82, N 4. -P. 931-948.
15. Mullarkey С.J., Edelstein D., Brownlee M.//Biochem. Biophys. Res. Commun. -1990. -Vol. 173. -P. 932-939.
16. O'Brien R. C, Luo M.//Metabolism. -1997. -Vol. 46, N 12. -Suppl. 1. -P. 22-25.
17. Phillips S., Thornalley P.//Eur. J. Biochem. -1993. -Vol. 212. -P. 101-105.
18. Regan T. J., Jyothirmayl G. N., Laham C., Jam А.//Adv. Exp. Med. Biol. -2001. -Vol. 498. -P. 127-132.
19. Richard J. P.//Biochem. Soc. Trans. -1993. -Vol. 21. -P. 549-553.
20. Rossini E., Wlernsperger N., Richard M. J. et al.//Diabetes. -1999. -Vol. 48. -P. 353-357.
21. Ruggiero-Lopez D., Lecomte M., Rellier N. et al.//Diabetologia. -1997. -Vol. 40. -Suppl. 1. -P. A310.
22. Ruggiero-Lopez D., Lecomte M., Moinet G. et al.//Biochem. Pharmacol. -1999. -Vol. 58. -P. 1765-1773.
23. Ruggiero-Lopez D., Howell S. K., Szwergold B. S. et al.//Diabetes. -2000. -Vol. 49. -Suppl. I. -P. A124.
24. Tanaka Y, Iwamoto H., Опита T. R. K.//Curr. Ther. Res. -1997. -Vol. 58. -P. 693-697.
25. Tanaka Y., Uchino H, Shimizu T. et al.//Eur. J. Pharmacol. -1999. -Vol. 376. -P. 17-22.
26. UKPDS: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33)//Lancet. -1998. -Vol. 352. -P. 837-853.
27. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS34) // Lancet. - 1998. - Vol. 352. - P. 854-865.
28. Uusitupa M., Niskanen L. K., Sutonen O.//Diabetologia. -1993. -Vol. 36. -P. 1175.
29. Yoshlno G, Hirano Т., Kazumi T.//Diabet. Res. Clin. Pract. -1996. -Vol. 33. -P. 1-14.
Review
For citations:
Nedosugova L.V., Lankin V.Z., Reznik S.M., Balabolkin M.I., Antonova K.V., Arzamastseva N.E., Konovalova G.G. Effect of metformin on the magnitude of oxidative stress in patients with type 2 diabetes mellitus. Problems of Endocrinology. 2007;53(1):3-7. (In Russ.) https://doi.org/10.14341/probl20075313-7
Views:
673
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
.jpg){kind=logo}
